Literature DB >> 2410456

Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.

C A Fulcher, J R Roberts, L Z Holland, T S Zimmerman.   

Abstract

The human Factor VIII procoagulant protein (VIII:C) purified from commercial Factor VIII concentrate consisted of a polypeptide doublet of 80,000 mol wt, a 92,000-mol wt polypeptide, and additional polypeptides of up to 188,000 mol wt. Thrombin digests contained a doublet of 72,000 mol wt, as well as 54,000- and 44,000-mol wt fragments. Proteolysis studies of purified VIII:C using thrombin and activated protein C have suggested that the 92,000- and 80,000 (or 72,000)-mol wt polypeptides comprise activated VIII:C. We have now used seven monoclonal antibodies raised against purified VIII:C to construct a preliminary epitope map of these VIII:C polypeptides. The specific VIII:C polypeptides with which the monoclonal antibodies reacted were determined by immunoblotting of VIII:C onto nitrocellulose sheets after reduced NaDodSO4-polyacrylamide gel electrophoresis. A minimum of five distinct epitopes were defined by these monoclonal anti-VIII:C antibodies. Identification of polypeptides bearing these epitopes allowed localization of distinct thrombin cleavage sites to the 92,000- and 80,000-mol wt chains, helped define polypeptide chain precursor-product relationships, and suggested that both the 92,000- and 80,000-mol wt polypeptides are necessary for VIII:C function. These data and their interpretation are consistent with the published description of the complete primary structure of VIII:C and its thrombin cleavage products. The 92,000- and 80,000-mol wt chains have been located at the amino- and carboxy-terminal ends of the molecule, respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410456      PMCID: PMC423722          DOI: 10.1172/JCI111933

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Letter: A more uniform measurement of factor VIII inhibitors.

Authors: 
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

5.  Structure of human factor VIII.

Authors:  G A Vehar; B Keyt; D Eaton; H Rodriguez; D P O'Brien; F Rotblat; H Oppermann; R Keck; W I Wood; R N Harkins; E G Tuddenham; R M Lawn; D J Capon
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

6.  Molecular cloning of a cDNA encoding human antihaemophilic factor.

Authors:  J J Toole; J L Knopf; J M Wozney; L A Sultzman; J L Buecker; D D Pittman; R J Kaufman; E Brown; C Shoemaker; E C Orr
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

7.  Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization.

Authors:  F T Liu; J W Bohn; E L Ferry; H Yamamoto; C A Molinaro; L A Sherman; N R Klinman; D H Katz
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

8.  Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies.

Authors:  J P Brown; P W Wright; C E Hart; R G Woodbury; K E Hellström; I Hellström
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

9.  Radioiodination of proteins by the use of the chloramine-T method.

Authors:  P J McConahey; F J Dixon
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

10.  D-3-Phosphoglycerate dehydrogenase from chicken liver. I. Purification.

Authors:  G A Grant; L M Keefer; R A Bradshaw
Journal:  J Biol Chem       Date:  1978-04-25       Impact factor: 5.157

View more
  11 in total

1.  Localization of a factor VIII-inhibiting antibody epitope to a region between residues 338 and 362 of factor VIII heavy chain.

Authors:  J Ware; J R Toomey; D W Stafford
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

2.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

3.  Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

Authors:  L O Andersson; N Forsman; K Huang; K Larsen; A Lundin; B Pavlu; H Sandberg; K Sewerin; J Smart
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.

Authors:  A M Aly; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

5.  Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.

Authors:  Yuichi Kamikubo; G Loredana Mendolicchio; Antonella Zampolli; Patrizia Marchese; Andrea S Rothmeier; Jennifer Nagrampa Orje; Andrew J Gale; Sriram Krishnaswamy; András Gruber; Henrik Østergaard; Lars C Petersen; Wolfram Ruf; Zaverio M Ruggeri
Journal:  Blood       Date:  2017-07-20       Impact factor: 22.113

6.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

Authors:  C A Fulcher; S de Graaf Mahoney; J R Roberts; C K Kasper; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

7.  Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine).

Authors:  M Arai; H Inaba; M Higuchi; S E Antonarakis; H H Kazazian; M Fujimaki; L W Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

8.  Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli.

Authors:  D Scandella; S DeGraaf Mahoney; M Mattingly; D Roeder; L Timmons; C A Fulcher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.

Authors:  P A Foster; C A Fulcher; R A Houghten; S de Graaf Mahoney; T S Zimmerman
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.

Authors:  A Leyte; K Mertens; B Distel; R F Evers; M J De Keyzer-Nellen; M M Groenen-Van Dooren; J De Bruin; H Pannekoek; J A Van Mourik; M P Verbeet
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.